Carefully administer at the dorsogluteal inj site due to proximity of the underlying sciatic nerve; possible inj site related events including sciatica, neuralgia, neuropathic pain & peripheral neuropathy. Patients w/ bleeding diatheses, thrombocytopenia or those taking anticoagulants. Possible thromboembolic events in women w/ advanced breast cancer. Potential risk of osteoporosis. May interfere w/ oestradiol measurement by immunoassay resulting in falsely elevated oestradiol levels. Possible asthenia; observe caution when driving or operating machinery. Mild to moderate hepatic & severe renal (CrCl <30 mL/min) impairment. Women of childbearing potential should use effective contraception during treatment & for 2 yr after the last dose. Not recommended for use in childn or adolescents.
Sign Out
